NO20062694L - Inhibitor av mutant form av KIT - Google Patents
Inhibitor av mutant form av KITInfo
- Publication number
- NO20062694L NO20062694L NO20062694A NO20062694A NO20062694L NO 20062694 L NO20062694 L NO 20062694L NO 20062694 A NO20062694 A NO 20062694A NO 20062694 A NO20062694 A NO 20062694A NO 20062694 L NO20062694 L NO 20062694L
- Authority
- NO
- Norway
- Prior art keywords
- kit
- inhibitor
- mutant form
- mutant
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Den foreliggende oppfinnelse vedrører behandling av KIT avhengige sykdommer som er karakterisert ved en mutant form av KIT hvorved KIT mutanten er identifisert og en passende inhibitor av KIT mutanten valgt fra midostaurin, vatalanib og forbindelse A er administrert.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52071403P | 2003-11-18 | 2003-11-18 | |
PCT/EP2004/013045 WO2005049032A1 (en) | 2003-11-18 | 2004-11-17 | Inhibitors of the mutant form of kit |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062694L true NO20062694L (no) | 2006-06-12 |
Family
ID=34619508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062694A NO20062694L (no) | 2003-11-18 | 2006-06-12 | Inhibitor av mutant form av KIT |
Country Status (28)
Country | Link |
---|---|
US (3) | US8017621B2 (no) |
EP (2) | EP1917965A1 (no) |
JP (3) | JP4762150B2 (no) |
KR (1) | KR101153647B1 (no) |
CN (3) | CN1882344A (no) |
AT (1) | ATE428426T1 (no) |
AU (1) | AU2004290902B2 (no) |
BR (1) | BRPI0416680A (no) |
CA (1) | CA2546189C (no) |
CY (1) | CY1110354T1 (no) |
DE (1) | DE602004020654D1 (no) |
DK (1) | DK1686997T3 (no) |
ES (1) | ES2324917T3 (no) |
HK (1) | HK1093680A1 (no) |
HR (1) | HRP20090390T1 (no) |
IL (2) | IL175578A (no) |
MA (1) | MA28176A1 (no) |
MX (1) | MXPA06005598A (no) |
NO (1) | NO20062694L (no) |
NZ (1) | NZ547195A (no) |
PL (1) | PL1686997T3 (no) |
PT (1) | PT1686997E (no) |
RU (2) | RU2362562C2 (no) |
SG (1) | SG139747A1 (no) |
SI (1) | SI1686997T1 (no) |
TN (1) | TNSN06138A1 (no) |
WO (1) | WO2005049032A1 (no) |
ZA (1) | ZA200603905B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
JP4762150B2 (ja) | 2003-11-18 | 2011-08-31 | ノバルティス アーゲー | Kitの変異体の阻害剤 |
CN101010082A (zh) * | 2004-08-31 | 2007-08-01 | 诺瓦提斯公司 | 米哚妥林用于治疗胃肠道基质瘤的用途 |
PL1879585T3 (pl) * | 2005-05-02 | 2013-08-30 | Novartis Ag | Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej |
CA2606068C (en) * | 2005-05-02 | 2013-10-29 | Novartis Ag | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
CN101267837B (zh) * | 2005-07-20 | 2010-12-15 | 彼得·瓦伦特 | 用于治疗系统性肥大细胞增生症的组合物 |
GT200600315A (es) * | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
RU2450814C2 (ru) * | 2005-12-06 | 2012-05-20 | Новартис Аг | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза |
JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
KR101579993B1 (ko) * | 2008-01-23 | 2015-12-23 | 노파르티스 아게 | 이마티닙을 이용한 티로신 키나제 수용체 kit에 의해 매개되는 증식성 질환의 치료를 최적화하는 방법 |
EP3076966A2 (en) * | 2013-12-02 | 2016-10-12 | BerGenBio AS | Use of kinase inhibitors |
CN106188028A (zh) * | 2015-05-05 | 2016-12-07 | 天津国际生物医药联合研究院 | 含恶二唑杂环类化合物及其制备方法和应用 |
WO2018014520A1 (zh) * | 2016-07-18 | 2018-01-25 | 嘉兴雅康博医学检验所有限公司 | 用于检测c-kit基因突变的引物、探针及试剂盒 |
CN116808044A (zh) | 2018-06-15 | 2023-09-29 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
TW202039862A (zh) * | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
US20210308133A1 (en) * | 2020-04-06 | 2021-10-07 | The Board Of Regents Of The University Of Texas System | Methods and compositions for inhibiting muscle wasting |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (no) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CA2148931A1 (en) | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6815791B1 (en) * | 1997-02-10 | 2004-11-09 | Fillfactory | Buried, fully depletable, high fill factor photodiodes |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
GB2325934A (en) | 1997-06-03 | 1998-12-09 | Polybiomed Ltd | Treating metal surfaces to enhance bio-compatibility and/or physical characteristics |
WO1998055152A1 (en) | 1997-06-06 | 1998-12-10 | Baylor College Of Medicine | The mast cell secretory machine as a target for anti-allergy drug development |
US5874603A (en) | 1997-07-15 | 1999-02-23 | Gelest, Inc. | Branched higher alkylsilanes |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
ES2326500T3 (es) | 1997-11-13 | 2009-10-13 | Mowycal Lending, Llc | Pequeños peptidos y metodos para el tratamiento del asma y la inflamacion. |
US20040157855A1 (en) * | 2001-04-05 | 2004-08-12 | Michael Heinrich | Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders |
US20050054617A1 (en) | 2001-06-29 | 2005-03-10 | Alain Moussy | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20050095237A1 (en) | 2001-12-11 | 2005-05-05 | Emtage Peter C. | Methods of therapy and diagnosis using targeting of cells that express P2Y10 |
US20050118600A1 (en) * | 2002-03-13 | 2005-06-02 | Yuko Aoki | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0223341D0 (en) | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
ATE489109T1 (de) * | 2003-09-19 | 2010-12-15 | Novartis Pharma Gmbh | Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin |
JP4762150B2 (ja) | 2003-11-18 | 2011-08-31 | ノバルティス アーゲー | Kitの変異体の阻害剤 |
PL1879585T3 (pl) | 2005-05-02 | 2013-08-30 | Novartis Ag | Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej |
CN200998572Y (zh) * | 2007-01-29 | 2008-01-02 | 深圳市龙岗区坪山宽富高尔夫器具厂 | 可携带配件的高尔夫球杆头套 |
JP5448036B2 (ja) * | 2009-02-18 | 2014-03-19 | トヨタ自動車株式会社 | カルボン酸の製造方法 |
-
2004
- 2004-11-17 JP JP2006540309A patent/JP4762150B2/ja active Active
- 2004-11-17 US US10/579,586 patent/US8017621B2/en active Active
- 2004-11-17 CA CA2546189A patent/CA2546189C/en not_active Expired - Fee Related
- 2004-11-17 EP EP08100447A patent/EP1917965A1/en not_active Withdrawn
- 2004-11-17 PT PT04818795T patent/PT1686997E/pt unknown
- 2004-11-17 RU RU2006121447/14A patent/RU2362562C2/ru not_active IP Right Cessation
- 2004-11-17 ES ES04818795T patent/ES2324917T3/es active Active
- 2004-11-17 NZ NZ547195A patent/NZ547195A/en not_active IP Right Cessation
- 2004-11-17 RU RU2009110449/15A patent/RU2405553C1/ru not_active IP Right Cessation
- 2004-11-17 MX MXPA06005598A patent/MXPA06005598A/es active IP Right Grant
- 2004-11-17 CN CNA2004800338582A patent/CN1882344A/zh active Pending
- 2004-11-17 DE DE602004020654T patent/DE602004020654D1/de active Active
- 2004-11-17 DK DK04818795T patent/DK1686997T3/da active
- 2004-11-17 KR KR1020067009584A patent/KR101153647B1/ko not_active IP Right Cessation
- 2004-11-17 AT AT04818795T patent/ATE428426T1/de active
- 2004-11-17 AU AU2004290902A patent/AU2004290902B2/en not_active Ceased
- 2004-11-17 CN CN200910169040A patent/CN101693031A/zh active Pending
- 2004-11-17 SI SI200431159T patent/SI1686997T1/sl unknown
- 2004-11-17 WO PCT/EP2004/013045 patent/WO2005049032A1/en active Application Filing
- 2004-11-17 PL PL04818795T patent/PL1686997T3/pl unknown
- 2004-11-17 SG SG200800338-6A patent/SG139747A1/en unknown
- 2004-11-17 CN CN201110222445.0A patent/CN102274230B/zh active Active
- 2004-11-17 BR BRPI0416680-9A patent/BRPI0416680A/pt not_active Application Discontinuation
- 2004-11-17 EP EP04818795A patent/EP1686997B1/en active Active
-
2006
- 2006-05-11 IL IL175578A patent/IL175578A/en not_active IP Right Cessation
- 2006-05-15 TN TNP2006000138A patent/TNSN06138A1/fr unknown
- 2006-05-16 ZA ZA200603905A patent/ZA200603905B/xx unknown
- 2006-05-24 MA MA29054A patent/MA28176A1/fr unknown
- 2006-06-12 NO NO20062694A patent/NO20062694L/no not_active Application Discontinuation
-
2007
- 2007-01-04 HK HK07100148.4A patent/HK1093680A1/xx not_active IP Right Cessation
-
2009
- 2009-07-08 HR HR20090390T patent/HRP20090390T1/hr unknown
- 2009-07-14 CY CY20091100748T patent/CY1110354T1/el unknown
-
2010
- 2010-02-04 US US12/700,106 patent/US8124611B2/en active Active
-
2011
- 2011-02-02 JP JP2011020873A patent/JP2011121973A/ja active Pending
-
2012
- 2012-01-25 US US13/357,972 patent/US20120157441A1/en not_active Abandoned
-
2013
- 2013-07-22 JP JP2013151605A patent/JP2013241438A/ja active Pending
- 2013-10-28 IL IL229124A patent/IL229124A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062694L (no) | Inhibitor av mutant form av KIT | |
NO20034056D0 (no) | Proliferative sykdommer | |
ECSP045429A (es) | Combinacion de compuestos organicos | |
NO20065117L (no) | Sammensetning omfattende en JNK inhibitor og syklosporin. | |
NO20051521L (no) | Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt | |
DE60329515D1 (de) | Analoga und prodrugs von buprenorphin | |
ATE510534T1 (de) | Naltrexonhydrochlorid-zusammensetzungen | |
NO20041452L (no) | 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. | |
ECSP055844A (es) | Nuevos compuestos triciclicos | |
NO20044402L (no) | Kombinasjonsbehandling av kemokine-medierte sykdommer | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
TW200603823A (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
BR0307998A (pt) | Hidroxietilaminas substituìdas | |
NO20050063L (no) | 2-heteroaryl karboksamider | |
EA200501584A1 (ru) | Бета-карболины, применяемые для лечения воспалительных заболеваний | |
ATE338036T1 (de) | Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate | |
ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
NO20054700L (no) | Anvendelse av et fibrat og orlistat for behandling av fedme | |
ATE359088T1 (de) | Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten | |
HN2003000228A (es) | Derivados benzufurano y benzotiofeno utiles en el tratamiento de desordenes hiper - proliferativos | |
NO20022883A (no) | Fremgangsmåte for behandling av trevirke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |